Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Insel Gruppe AG, University Hospital Bern
With
Swiss National Science Foundation
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically proven prostate cancer (T1-2N0M0 Gleason score 6-10) scheduled for radical prostatectomy or patients with histologically proven bladder cancer (T1-3bN0M0G3) scheduled for cystectomy
Written informed consent to participate in this trial.
You may not be if
Patients with contraindications for MRI (e.g. pacemaker, metal implants, claustrophobia).
Patients in a critical cardiovascular state, with risk of decompensation after administration of the USPIO contrast agent.
Patients with hemochromatosis or an allergy to dextran or iron compounds.
Pregnant or breast-feeding women.
Patients who have received gadolinium complexes within 2 days or iron oxide particles within 7 days before MRI.
Patients who underwent chemotherapy or radiotherapy before surgery.
Patients whose degree of cooperation is incompatible with carrying out the study.
Patients with contraindications to Glucagon administration.
Clareo Health | USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases
